Lyme Opportunity InBios is actively developing a Lyme diagnostic test, signaling expansion into tick-borne disease diagnostics which creates a potential cross-sell opportunity for laboratories and clinics seeking broader infectious disease panels.

Serology Expansion Recent launch of an in vitro serological ELISA kit for Strongyloides infection demonstrates product diversification and a pathway to enter clinical labs and reference laboratories with turnkey serology solutions.

Emerging Threat Focus Specialization in diagnostics for emerging infectious diseases and biothreats positions InBios to pursue government, defense, and public health contracts requiring rapid deployment and validated POC or ELISA platforms.

Quality & Compliance GMP compliant, FDA registered, USDA licensed, and ISO 13485:2016 certified credentials support sales conversations with hospitals, labs, and distributors prioritizing quality management and regulatory readiness.

Strategic Partnerships Past collaborations with Tactical Defense Media, Curebase, and Code 1 Supply indicate a strong channel of partnerships and contract vehicles, suggesting targeted pitches to distributors and integrators for scale and faster market access.